| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
225,410,000 |
| Market
Cap: |
135.25(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4783 - $1.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Co.'s clinical-stage product candidates include: Seralutinib, also known as GB002, which is an inhaled small molecule, platelet-derived growth factor receptor colony-stimulating factor 1 receptor and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, which is an oral small molecule for the treatment of inflammatory bowel disease; and GB5121, which an oral small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
232,000 |
1,400,505 |
| Total Buy Value |
$0 |
$0 |
$138,093 |
$2,465,139 |
| Total People Bought |
0 |
0 |
2 |
5 |
| Total Buy Transactions |
0 |
0 |
2 |
12 |
| Total Shares Sold |
44,068 |
44,068 |
45,882 |
92,014 |
| Total Sell Value |
$52,319 |
$52,319 |
$54,659 |
$336,499 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
5 |
5 |
6 |
14 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Peterson Caryn |
EVP, Regulatory Affairs |
• – – |
2021-10-25 |
4 |
S |
$12.25 |
$29,118 |
D/D |
(2,377) |
72,451 |
|
27% |
|
| Aranda Richard |
Chief Medical Officer |
• – – |
2021-10-25 |
4 |
S |
$12.25 |
$29,118 |
D/D |
(2,377) |
217,432 |
|
27% |
|
| Carter Laura |
Chief Scientific Officer |
• – – |
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
97,683 |
|
- |
|
| Aranda Richard |
Chief Medical Officer |
• – – |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
219,809 |
|
- |
|
| Carter Laura |
Chief Scientific Officer |
• – – |
2021-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,820 |
72,683 |
|
- |
|
| Peterson Caryn |
EVP, Regulatory AffairsOfficer |
• – – |
2021-04-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
64,008 |
|
13% |
|
| Peterson Caryn |
EVP, Regulatory Affairs |
• – – |
2021-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,820 |
74,828 |
|
- |
|
32 Records found
|
|
Page 2 of 2 |
|
|
0.03 (4.71%) 
